Patented Drug Extension Strategies on Healthcare Spending: A Cost-Evaluation Analysis

PLoS Medicine

Volumn 10, Issue 6, 2013, Pages

  Vernaz, Nathalie ^a,b   Haller, Guy ^a,b,c   Girardin, François ^a,d   Huttner, Benedikt ^a   Combescure, Christophe ^b   Dayer, Pierre ^a   Muscionico, Daniel ^e   Salomon, Jean Luc ^e   Bonnabry, Pascal ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF YORK   (United Kingdom)

^e Invoice Office   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CETIRIZINE; CITALOPRAM; COLECALCIFEROL; DESLORATADINE; ESCITALOPRAM; ESOMEPRAZOLE; EZETIMIBE PLUS SIMVASTATIN; GABAPENTIN; GENERIC DRUG; LEVOCETIRIZINE; LORATADINE; OMEPRAZOLE; PREGABALIN; SIMVASTATIN; ZOLPIDEM;

ARTICLE; COST BENEFIT ANALYSIS; DRUG MANUFACTURE; HEALTH CARE; HEALTH CARE PERSONNEL; HUMAN; PATENT; PHARMACY; PHYSICIAN; PRESCRIPTION; SENSITIVITY ANALYSIS;

CETIRIZINE; COSTS AND COST ANALYSIS; ESOMEPRAZOLE; FEMALE; FORMULARIES, HOSPITAL; HEALTH CARE COSTS; HUMANS; MALE; MARKETING; MIDDLE AGED; NONPRESCRIPTION DRUGS; PATENTS AS TOPIC; PRESCRIPTION DRUGS; RESIDENCE CHARACTERISTICS; TIME FACTORS;

EID: 84879351269     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001460     Document Type: Article

References (29)

1. Agranat II, Caner H, (1999) Intellectual property and chirality of drugs. Drug Discov Today 4: 313-321.
2. Munos B, (2009) Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 8: 959-968.
3. Timonen J, Karttunen P, Bengtstrom M, Ahonen R, (2009) The impact of generic substitution on the turnover and gross margin of pharmaceutical companies a survey 1 year and 5 years after the introduction of generic substitution in Finland. Health Policy 92: 116-123.
4. Lexchin J, (2004) The effect of generic competition on the price of brand-name drugs. Health Policy 68: 47-54.
5. Hughes DA, Ferner RE, (2010) New drugs for old: disinvestment and NICE. BMJ 340: c572.
6. Somogyi A, Bochner F, Foster D, (2004) Inside the isomers: the tale of chiral switches. Australian Prescriber 27: 47-49.
7. Hitchings AW, Baker EH, Khong TK, (2012) Making medicines evergreen. BMJ 345: e7941.
8. Agranat I, Caner H, Caldwell J, (2002) Putting chirality to work: the strategy of chiral switches. Nat Rev Drug Discov 1: 753-768.
9. Amin T, Kesselheim AS, (2012) Secondary patenting of branded pharmaceuticals: a case study of how patents on two HIV drugs could be extended for decades. Health Aff (Millwood) 31: 2286-2294.
10. Wang YR, Pauly MV, (2005) Spillover effects of restrictive drug formularies: a case study of PacifiCare in California. Am J Manag Care 11: 24-26.
11. Tordoff JM, Murphy JE, Norris PT, Reith DM, (2006) Use of centrally developed pharmacoeconomic assessments for local formulary decisions. Am J Health Syst Pharm 63: 1613-1618.
12. Ljungberg C, Lindblad AK, Tully MP, (2007) Hospital doctors' views of factors influencing their prescribing. J Eval Clin Pract 13: 765-771.
13. The Federal Authorities of the Swiss Confederation (1994) Loi fédérale du 18 mars 1994 sur l'assurance-maladie (LAMal). RS 832.10. Available: http://www.admin.ch/ch/f/rs/c832_10.html. Accessed 30 April 2013.
14. Muijrers PE, Grol RP, Sijbrandij J, Janknegt R, Knottnerus JA, (2005) Differences in prescribing between GPs: impact of the cooperation with pharmacists and impact of visits from pharmaceutical industry representatives. Fam Pract 22: 624-630.
15. WHO Collaborating Centre for Drug Statistics Methodology (2013) ATC/DDD index 2013 [database]. Available: http://www.whocc.no/atc_ddd_index/. Accessed 30 April 2013.
16. Helfenstein U, (1996) Box-Jenkins modelling in medical research. Stat Methods Med Res 5: 3-22.
17. Morgan OW, Griffiths C, Majeed A, (2007) Interrupted time-series analysis of regulations to reduce paracetamol (acetaminophen) poisoning. PLoS Med 4: e105 doi:10.1371/journal.pmed.0040105.
18. Dylst P, Simoens S, (2011) Does the market share of generic medicines influence the price level?: a European analysis. Pharmacoeconomics 29: 875-882.
19. Peterson LR, (2005) Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance. Clin Microbiol Infect 11 (Suppl 5):: 4-16.
20. Svensson S, Mansfield PR, (2004) Escitalopram: superior to citalopram or a chiral chimera? Psychother Psychosom 73: 10-16.
21. Landefeld CS, Steinman MA, (2009) The Neurontin legacy-marketing through misinformation and manipulation. N Engl J Med 360: 103-106.
22. Vedula SS, Bero L, Scherer RW, Dickersin K, (2009) Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med 361: 1963-1971.
23. Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, et al. (2001) Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 96: 656-665.
24. Sondergaard J, Vach K, Kragstrup J, Andersen M, (2009) Impact of pharmaceutical representative visits on GPs' drug preferences. Fam Pract 26: 204-209.
25. Feely J, Chan R, McManus J, O'Shea B, (1999) The influence of hospital-based prescribers on prescribing in general practice. Pharmacoeconomics 16: 175-181.
26. Achermann R, Suter K, Kronenberg A, Gyger P, Muhlemann K, et al. (2011) Antibiotic use in adult outpatients in Switzerland in relation to regions, seasonality and point of care tests. Clin Microbiol Infect 17: 855-861.
27. Grant K, Al-Adhami N, Tordoff J, Livesey J, Barbezat G, et al. (2006) Continuation of proton pump inhibitors from hospital to community. Pharm World Sci 28: 189-193.
28. Greene JA, Kesselheim AS, (2011) Why do the same drugs look different? Pills, trade dress, and public health. N Engl J Med 365: 83-89.
29. Wu EQ, Yu AP, Lauzon V, Ramakrishnan K, Marynchenko M, et al. (2011) Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder. Ann Pharmacother 45: 441-451.